INTRODUCTION
============

The Tat (twin-arginine translocation) protein transport pathway exports proteins across the cytoplasmic membranes of bacteria and archaea, and the thylakoid membranes of plant chloroplasts \[[@B1],[@B2]\]. Protein substrates of the Tat pathway are folded before translocation and are targeted to the Tat machinery by cleavable N-terminal signal peptides containing an almost invariant pair of arginine residues \[[@B3]\]. Transport by the Tat pathway is energized solely by the protonmotive force \[[@B1],[@B2]\].

The model bacterium *Escherichia coli* K-12 produces 28 proteins bearing twin-arginine signal peptides. Approximately two-thirds of these proteins are known or predicted to contain redox cofactors and some of them also form complexes with partner subunits that lack a signal peptide before export \[[@B4]\]. The complexity of these Tat substrates necessitates a pre-export 'proofreading' process to ensure that only folded and assembled proteins are presented for translocation. One hypothesis involves dedicated chaperone proteins that interact directly with twin-arginine signal peptides to prevent premature targeting of the substrate before cofactor insertion and binding of any protein partners \[[@B5]\].

The *E. coli* TMAO (trimethylamine *N*-oxide) reductase TorA is a soluble periplasmic enzyme containing the MGD (molybdopterin guanine dinucleotide) cofactor at its active site \[[@B6]\]. TorA is a well-characterized substrate of the Tat pathway; indeed, transport of TorA to the periplasm was found to be blocked in a mutant strain that was unable to synthesize MGD, which led to the original hypothesis that a transport pathway for folded proteins may exist in bacteria \[[@B7]\]. The TorA protein is encoded by the *torCAD* operon ([Figure 1](#F1){ref-type="fig"}A) where TorC is a haem-containing quinol oxidase and TorD is a cytoplasmic protein \[[@B8]\]. Cellular levels of enzymatically active TorA are significantly reduced in a strain lacking the *torD* gene \[[@B9]\], and the TorD protein was found subsequently to interact with an unfolded (heat-denatured) form of the mature TorA enzyme \[[@B9]\]. This initial work therefore established that there was a clear binding site for TorD within the mature region of the protein and suggested a role for TorD in loading the MGD cofactor into the TorA apoenzyme \[[@B9],[@B10]\]. In addition to this, a subsequent genetic screen identified TorD as a binding partner for the TorA twin-arginine signal peptide \[[@B11]\]. This was confirmed *in vitro* when recombinant TorD was shown to bind directly to the isolated TorA signal peptide with a 1:1 stoichiometry and an apparent *K*~d~ of \~59 nM \[[@B12],[@B13]\]. The binding epitope for TorD has been mapped to the C-terminal end of the TorA signal peptide, close to its junction with the mature portion of the enzyme \[[@B12],[@B14]\]. Interestingly, binding of the TorA signal peptide by TorD seems to be an activity not strictly connected with cofactor loading, since co-expression of *torD* can enhance the export of synthetic signal peptide fusion proteins on the Tat pathway \[[@B11],[@B15]\]. The TorD protein itself is 22.5 kDa and is known to exist in equilibrium between monomeric and dimeric forms \[[@B16]--[@B18]\], have a low level of GTPase activity associated with the dimeric form \[[@B18]\], and have the ability to bind the MGD cofactor *in vitro* \[[@B19]\]. However, although it is clear that the monomeric form of TorD can bind the isolated TorA signal peptide \[[@B12],[@B13]\], the physiological role and significance of TorD dimerization is not clear.

![Tools for the isolation of TorAD complexes\
(**A**) A cartoon representing the structure of the *torCAD* operon located at 22.8 min on the *E. coli* chromosome. The names of the protein products of the genes are given above the arrows. (**B**) An overexpression vector based on pQE80 (Qiagen) encoding full-length TorA and TorD*^His^*. The natural transcriptional and translational coupling between *torA* and *torD* is maintained. (**C**) An expression vector encoding TorA lacking its entire Tat signal peptide comprising Asn^2^--Ala^39^ (TorA~Δsp~, TorA Δ2--39) and TorD*^His^*. (**D**) An expression vector encoding TorA lacking its entire C-terminal Domain IV comprising Ile^676^--Ser^848^ (TorA~ΔCT~, TorA Δ676--848) and TorD*^His^*.](bj2012-1832i001){#F1}

Current models for TorA biosynthesis assume that TorD interacts with the TorA precursor by binding at two distinct sites: one being within the twin-arginine signal peptide with the other, uncharacterized, site lying elsewhere in the mature portion of the protein \[[@B5],[@B20]\]. These two binding events are thought to not only delay the Tat transport event, but also actively facilitate efficient insertion of the MGD cofactor into the apoenzyme. This pre-export 'Tat proofreading' process would be completed by the controlled release of the bound chaperones and subsequent translocation of the folded active enzyme to the periplasm. However, it is not known whether each of the TorD-binding sites on the TorA apoenzyme are bound by separate TorD monomers or a single TorD dimer, or whether the TorD monomer itself contains two distinct TorA-binding sites. Moreover, the degree of folding of the TorA precursor when bound by TorD has not been explored, and it remains a mystery how release of the chaperones is ultimately triggered.

In the present study, a stable and cofactor-free complex of TorD with the TorA apoenzyme has been isolated, both with and without the twin-arginine signal peptide. Using a combination of biophysical and biochemical approaches, we have demonstrated that a single TorD monomer binds directly to a single TorA apoprotein regardless of the presence of the signal peptide. This suggests that a single TorD monomer recognizes two binding sites on the TorA polypeptide and that these epitopes are nearby or overlapping. Finally, we have demonstrated that binding of TorA by TorD changes the conformation of apo-TorA in relation to the mature active enzyme by inducing exposure of the C-terminal domain of the TorA protein.

EXPERIMENTAL
============

Plasmid and strain construction
-------------------------------

The *torAD* genes form a transcription unit on the *E. coli* chromosome with overlapping stop and start codons. To co-overproduce TorA and TorD*^His^*, this natural translational coupling was retained. DNA encoding SPA (sequential peptide affinity)-tagged TorD along with TorA was amplified from the chromosome of *E. coli* strain DY330 *torD-SPA* \[[@B21],[@B22]\] using oligonucleotides TorAMfeIup (5′-GCGCCAATTGCGATAAGAAGGAAGAAAAATAATG-3′) and SPASphIdown (5′-GCGCGCATGCCTACTTGTCATCGTCATCC-3′). The resulting PCR product was digested with MfeI and SphI and cloned into pQE80 digested previously with EcoRI and SphI. To replace DNA encoding the SPA-tagged variant of TorD with a His-tagged variant, the pQE80torADSPA plasmid was digested with NheI (which removes DNA covering the 3′-end of *torD*, the SPA-tag-coding sequence and a small region of the vector). Plasmid pQE60torD \[[@B13]\] which codes for a C-terminally His-tagged TorD was also digested with NheI and the fragment covering the 3′-end of *torD* along with the His-tag-coding sequence was ligated into the digested pQE80torADSPA vector. Resultant clones were analysed by sequencing to ensure that the NheI fragment had been cloned into the correct orientation, and the construct was designated pQE80TorADhis ([Figure 1](#F1){ref-type="fig"}B).

To overproduce TorD*^His^* along with TorA lacking its N-terminal signal peptide, the encoding DNA was amplified using oligonucleotides TorAMfeIdelSS (5′-GCGCCAATTGCGATAAGAAGGAAGAAAAATAATGGCGCAAGCGGCGACTGACGCTGTCATCTCG-3′) and QEreverse (5′-GTTCTGAGGTCATTACTGGAT-3′), with pQE80 TorADhis as a template. The resultant PCR product was digested with MfeI and HindIII and cloned into pQE80 that had been pre-digested with EcoRI and HindIII, to give construct pQE80TorAdelSSDhis ([Figure 1](#F1){ref-type="fig"}C).

To produce a C-terminally truncated TorA along with TorD*^His^*, a fragment of *torA* terminating at codon 675 and followed by a stop codon was amplified with oligonucleotides TorAfor (5′-GACCTCAACCTGCCGCTTTGC-3′) and TorA675STOPHindIII (5′-GCGCAAGCTTATTTCTCAAACCACATCGGATGCCC-3′) and digested with NruI (the recognition site for which is present in the *torA* gene) and HindIII. A second PCR product covering the *torD* ribosome-binding site and a fragment of the *torD* gene was amplified with oligonucleotides TorDHindRBS (5′-GCGCAAGCTTGCAGGTGAAATCATGACCACG-3′) and TorDrev (5′-GGTCATCAGAAACAGGCCGC-3′) and digested with HindIII and SacII (the recognition site for SacII occurs naturally in *torD*). A three-way ligation was carried out with these two fragments and pQE80TorADhis that had been digested previously with NruI and SacII. The resultant clone was designated pQE80TorAtruncDhis ([Figure 1](#F1){ref-type="fig"}D).

Strain FTH007 encodes a C-terminally hexahistidine-tagged TorA produced from the native chromosomal location and was constructed as follows. A 582 bp fragment of *torA* DNA finishing immediately before the *torA* stop codon was amplified with oligonucleotides TorAHis1 (5′-GCGCCCATGGCTCGAAAACTATCGCCGATATGAAC-3′) and TorAHis2 (5′-GCGCAGATCTTGATTTCACCTGCGACGCGGGAAC-3′), digested with NcoI and BglII and cloned into similarly digested pFAT210 \[[@B23]\]. DNA covering the *torD* ribosome-binding site and approximately 600 nucleotides of downstream DNA was amplified with oligonucleotides TorAHis3 (5′-GCGCAAGCTTTGTTCCCGCGTCGCAGGTGAAATC-3′) and TorAHis4 (5′-GCGCTCTAGAGACGTTATCTGTTTTGGTGGTCGC-3′), digested with XbaI and HindIII and cloned into the above construct. DNA covering the *torAhis* allele was subsequently excised by digestion with XbaI and KpnI and cloned into similarly digested pMAK705 \[[@B24]\]. The *torAhis* allele was then moved on to the chromosome of strain DSS401 (as MC4100, Δ*dmsABC*::Kan^R^) \[[@B25]\] to give strain FTH007.

All constructs were fully sequenced to ensure that no mistakes had been introduced inadvertently during the cloning procedure.

TMAO reductase assays
---------------------

TMAO reductase assays were performed using strain GB426 (as MC4100, Δ*torCAD*::Apr^R^, Δ*dmsABC*::Kan^R^ \[[@B22]\]), which contained either pQE80, pQE80TorADhis, pQE80TorAdelSSDhis or pQE80TorAtruncDhis. Cells were cultured anaerobically overnight in LB (Luria--Bertani) medium supplemented with 0.5% glycerol and 0.4% TMAO, along with the antibiotics apramycin (50 μg/ml), kanamycin (25 μg/ml) and ampicillin (100 μg/ml). Cells were harvested, washed and lysed by passage through a French press pressure cell as described previously \[[@B26]\]. After removal of unbroken cells and debris by a short centrifugation step, the resultant crude cell extract was assayed for TMAO reductase activity essentially as described previously \[[@B6],[@B27]\]. Protein concentration was determined using the Lowry assay \[[@B28]\].

Preparation of recombinant proteins
-----------------------------------

All plasmid-encoded TorA/TorD*^His^* proteins were overproduced and purified in an identical manner. A single colony of freshly transformed *E. coli* BL21(DE3) \[F^−^ *ompT hsdS*(r~B~^−^ m~B~^−^) *gal dcm* λ(DE3)\] was cultured overnight in 5 ml of LB medium supplemented with 100 μg/ml ampicillin. This provided the inoculum for a 500 ml culture, which was grown aerobically at 37°C and at 140 rev./min in a baffled 2 litre flask to a *D*~600~ of 0.6 before induction of recombinant protein production by addition of 2 mM IPTG (isopropyl β-[d]{.smallcaps}-thiogalactopyranoside), followed by a temperature shift to 18°C. After 16 h, cells were harvested and resuspended (10 ml per 1 g of cells) in buffer A \[50 mM Tris/HCl (pH 7.5), 200 mM KCl, 1 mM DTT (dithiothreitol) and 25 mM imidazole\]. Protease inhibitor \[EDTA-free Complete™ protease inhibitor cocktail (Roche)\], lysozyme and DNase were added to the resuspension and cells were lysed using an Emulsiflex C3 high-pressure homogenizer. Cell debris was removed by centrifugation at 18850 ***g*** for 15 min, followed by removal of membranes by ultracentifugation at 45000 rev./min for 1 h using a Beckman Ti70 rotor. All centrifugation steps were conducted at 4°C. The supernatant obtained following ultracentrifugation was filtered through a 0.22-μm-pore-size membrane filter (Millipore) before being subjected to IMAC (immobilized metal-ion-affinity chromatography) as follows. The extract was loaded on to a 5 ml HisTrap column (GE Healthcare) equilibrated with buffer A. After extensive washing with buffer A, hexahistidine-tagged proteins were subsequently eluted using a gradient of 25--500 mM imidazole in buffer A. TorA/TorD*^His^*-containing fractions were identified by SDS/PAGE (12% gels), pooled and concentrated to 2 ml using a Vivaspin 20 spin concentrator (10 kDa cut-off, Sartorius). The concentrated sample was then loaded on to a calibrated HiLoad 16/60 Superdex 200 Prep Grade (GE Healthcare) size-exclusion column equilibrated with buffer A (50 mM Tris/HCl, pH 7.5, 200 mM KCl and 1 mM DTT), with TorA/TorD*^His^*-containing fractions again identified by SDS/PAGE (12% gels).

Chromosomally encoded TorA*^His^* was purified from cells that had been cultured anaerobically in 5 litre capped bottles that had been filled with LB medium supplemented with 0.4% TMAO, 0.5% glycerol and 50 μg/ml kanamycin. After inoculation with a 5 ml pre-culture, bottles were incubated for 16 h without shaking at 37°C. Cells were harvested, washed and resuspended to a final concentration of 10 ml/g of cells in 50 mM Tris/HCl (pH 7.5) and 40% (w/v) sucrose. The suspension was then supplemented with EDTA (5 mM final concentration) and 0.6 mg/ml lysozyme and incubated for 30 min at 37°C to release the periplasmic fraction. Sphaeroplasts were removed by centrifugation at 12500 rev./min for 20 min using a Beckman JA-25.50 rotor at 4°C and the supernatant was retained. The EDTA was removed by dialysis in buffer A before loading the supernatant on to a 5 ml HisTrap column and purifying as above.

SAXS (small-angle X-ray scattering)
-----------------------------------

SAXS data using purified TorD*^His^*, TorA/TorD*^His^* and TorA~ΔSP~/TorD*^His^* samples were recorded on the ID14-3 BioSAXS beamline at the European Synchrotron Radiation Facility (ESRF Grenoble, France). Sample-detector distance was 2.43 m for an X-ray wavelength of 0.931 Å (1 Å=0.1 nm). Then, 50 μl sample and buffer volumes were loaded in a flowthrough quartz capillary cell at 25°C. The sample volume exposed to the X-ray beam was approximately 10 μl. Samples were checked for radiation damage by using ten successive exposure times of 10 s each. Final exposure time was 100 s for all samples/buffers. The two-dimensional diffraction patterns were normalized to an absolute scale and azimuthally averaged to obtain the intensity profiles I(Q), within BSxCuBE (ESRF beamline data collection software). Solvent contributions (buffer backgrounds collected before and after every protein sample) were averaged and subtracted from the associated protein sample using the program PRIMUS \[[@B29]\].

CD analysis
-----------

CD analysis of protein samples was provided as a service by the Scottish Circular Dichroism Facility, University of Glasgow. Spectra of protein solutions were obtained using a JASCO J-810 spectropolarimeter. Far-UV CD measurements (185--260 nm) were collected in quartz cells of 0.02 cm pathlength at 25°C with a scan speed of 10 nm/min, bandwidth of 1 nm, response of 2 s and data pitch of 0.2 nm. Before collection of CD data, proteins were buffer-exchanged into CD-appropriate buffer (50 mM Tris/H~2~SO~4~, pH 7.5, 200 mM K~2~SO~4~ and 1 mM DTT). Protein concentrations were estimated using a NanoDrop spectrophotometer before the experiment. Near-UV CD measurements (250--320 nm) were obtained in a 0.2-cm-pathlength quartz cuvette using the following parameters: temperature, 25°C; scan speed, 10 nm/min; bandwidth, 1 nm; response, 2.0 s; and data pitch, 0.2 nm. Protein was analysed in appropriate buffer (50 mM Tris/HCl, pH 7.5, 200 mM KCl and 1 mM DTT). The spectra were corrected for protein concentration and cell pathlength before being analysed by DichroWeb (<http://dichroweb.cryst.bbk.ac.uk>), an online server which hosts the various algorithms used to estimate protein secondary structures.

Metal analysis
--------------

Metal content was analysed by ICP-AES (inductively coupled plasma--atomic emission spectrometry)/ICP-MS (inductively coupled plasma--MS) and was provided as a service by the School of Chemistry at the University of Edinburgh.

Limited trypsinolysis of TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes
-------------------------------------------------------------------------------

Protein samples (1 mg/ml in 50 mM Tris/HCl, pH 7.5, 200 mM KCl and 1 mM DTT; 100 μl final volume) were incubated with 1% (w/w) trypsin (porcine pancreas, proteomics grade, Sigma--Aldrich) at 37°C. Aliquots of 5 μl were withdrawn at various intervals and the reaction stopped by addition of 20 μl of Laemmli buffer (Bio-Rad Laboratories) followed by immediate boiling for 10 min. Once the time course was completed, samples were analysed by SDS/PAGE (12% gels).

Proteins were identified by tryptic peptide mass fingerprinting of gel slices performed by the FingerPrints Proteomic Service (College of Life Sciences, University of Dundee).

Analysis of TorA--TorD*^His^* complexes by SEC (size-exclusion chromatography)--MALLS (multi-angle laser light scattering)
--------------------------------------------------------------------------------------------------------------------------

Size estimates of TorA--TorD*^His^* complexes were obtained by SEC--MALLS, which was provided as a service by the University of York Bioscience Technology Facility. Measurements were conducted on a system comprising a Wyatt HELEOS-II multi-angle light-scattering detector and a Wyatt rEX refractive index detector linked to a Shimadzu HPLC system (SPD-20A UV detector, LC20-AD isocratic pump system, DGU-20A3 degasser and SIL-20A autosampler). Work was conducted at room temperature (20±2°C). Solvent was filtered through a 0.2-μm-pore-size filter before use and a further 0.1-μm-pore-size filter was present in the flow path. Filtered (0.2 μm pore size) TorA--TorD*^His^* samples (100 μl, corresponding to 100 μg of protein) were applied to a Superdex 200 10/300 GL column (GE Healthcare) equilibrated with 50 mM Tris/HCl (pH 7.5), 200 mM KCl and 1 mM DTT at 0.5 ml/min; Shimadzu LC Solutions software was used to control the HPLC, and Astra V software was used for the HELEOS-II and rEX detectors. BSA was used for molecular mass calibration. The Astra data collection was 1 min shorter than the LC solutions run to maintain synchronization. Blank buffer injections were used as appropriate to check for carry-over between sample runs. Data were analysed using the Astra V software. MWs were estimated using the Zimm fit method \[[@B30]\] with degree 1. A value of 0.19 was used for protein refractive index increment (d*n*/d*c*).

RESULTS
=======

Isolation of a TorA--TorD*^His^* complex
----------------------------------------

Isolation of a complex between untagged TorA and affinity-tagged TorD was originally demonstrated on a small scale using a C-terminally SPA-tagged form of TorD \[[@B22]\]. In order to scale up the co-expression system to allow detailed analysis of the complex, the original *torAD^SPA^* allele was cloned into expression vector pQE80 and the DNA coding for the SPA tag at the C-terminus of TorD replaced with a hexahistidine tag ([Figure 1](#F1){ref-type="fig"}B). The soluble cell extract containing overproduced TorA and TorD*^His^* was subjected to IMAC and fractions containing proteins of the expected size of TorA and TorD*^His^* were identified in a single peak at 110 mM imidazole. The IMAC samples were pooled, concentrated and subjected to SEC using a HiLoad 16/60 Superdex 200 Prep Grade column. As shown in [Figure 2](#F2){ref-type="fig"}(A), protein was eluted at 78.5 ml, corresponding to an estimated molecular mass of 114 kDa. Analysis of the peak fraction by SDS/PAGE revealed the presence of two major proteins ([Figure 2](#F2){ref-type="fig"}B), which were confirmed by tryptic peptide mass fingerprinting to be TorA and TorD*^His^*. The overall protein yield from this process was approximately 1.5 mg/g of bacterial cells.

![Isolation of a TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complex\
(**A** and **C**) TorD*^His^*-containing fractions after metal chelate chromatography of cell extracts overproducing (**A**) TorA and TorD*^His^* or (**C**) TorA~ΔSP~ and TorD*^His^* were pooled, concentrated and applied to a HiLoad 16/60 Superdex 200 Prep Grade size-exclusion column. Eluted protein was monitored by measuring absorbance at 280 nm. The column was calibrated with the standard proteins ribonuclease (14 kDa), carbonic anhydrase (29 kDa), ovalbumin (44 kDa), conalbumin (75 kDa), aldolase (158 kDa) and ferritin (440 kDa), and the linear regression analysis is shown as inset boxes. *R*^2^=0.9976, *y*=−23.5*x*+126.83. MW, molecular mass. (**B** and **D**) SDS/PAGE analysis (12% gels) of (**B**) the concentrated fractions after metal chelate chromatography (Ni pool), and the non-concentrated and concentrated peak fractions from SEC of the TorA--TorD*^His^* complex and (**D**) the concentrated peak fraction from SEC of the TorA~ΔSP~--TorD*^His^* complex. Molecular masses are indicated in kDa.](bj2012-1832i002){#F2}

It was notable during the purification of TorAD*^His^*, particularly following concentration of the samples, that more than one electrophoretic form of TorA was evident by SDS/PAGE. A low-percentage acrylamide gel was therefore used to separate these forms, which were excised and analysed by tryptic peptide mass fingerprinting. The analysis showed that, whereas the majority of the TorA was present as full-length intact polypeptide, there was a proportion of TorA that had undergone limited proteolysis and was lacking up to 150 amino acids from its C-terminal end (Supplementary Figure S1 at <http://www.biochemj.org/bj/452/bj4520057add.htm>). In addition, in some instances, up to 12 amino acid residues could be lost from the N-terminus of TorA. It is concluded that, whereas a complex of TorAD*^His^* is stable to purification, the extremities of TorA can be subjected to variable levels of proteolysis during isolation.

Removal of the entire Tat signal peptide from the TorA protein (TorA Δ2--39) still allows isolation of a stable complex with TorD*^His^*
----------------------------------------------------------------------------------------------------------------------------------------

As well as signal peptide binding, previous biochemical and genetic experiments pointed to a binding site for TorD within the mature region of the TorA enzyme (e.g. \[[@B9],[@B10]\]). To investigate this further, a vector was designed that would co-overproduce a version of TorA lacking its entire 39-residue Tat signal peptide (TorA~ΔSP~) with TorD*^His^* ([Figure 1](#F1){ref-type="fig"}C). When TorD*^His^* was isolated from the soluble cell fraction by IMAC, a protein of the expected size of TorA~ΔSP~ was also co-purified. The TorD*^His^*-containing fractions were pooled, concentrated and applied to a Superdex 200 size-exclusion column. The TorD*^His^* eluted at 78.8 ml, corresponding to an estimated molecular mass of 110 kDa ([Figure 2](#F2){ref-type="fig"}C) and analysis of the concentrated peak fraction by SDS/PAGE revealed the presence of two major proteins ([Figure 2](#F2){ref-type="fig"}D), which were confirmed by tryptic peptide mass fingerprinting to be TorA~ΔSP~ and TorD*^His^*. Thus it is clear that a stable complex of TorD*^His^* and TorA can be isolated in the absence of the twin-arginine signal peptide.

TorD*^His^* binds the full-length TorA precursor, and the TorA~Δsp~ species lacking its entire signal peptide (Δ2--39), at a 1:1 stoichiometry
----------------------------------------------------------------------------------------------------------------------------------------------

SEC indicates that the complex of TorD*^His^* with TorA elutes at a similar molecular mass regardless of whether the signal peptide was present on TorA ([Figure 2](#F2){ref-type="fig"}). A more accurate technique is SEC--MALLS, which uses HPLC-linked SEC coupled with static laser light scattering to provide a direct measure of molecular mass. Using this technique, the TorA--TorD*^His^* complex was observed to exhibit a mass range of 100--120 kDa and a peak mass of 114.7 kDa ([Table 1](#T1){ref-type="table"}), which is very close to the calculated mass (117.9 kDa) for a 1:1 complex of the two proteins ([Table 1](#T1){ref-type="table"}). The TorA~ΔSP~--TorD*^His^* complex exhibited a mass range of 95--115 kDa and a peak mass of 108.2 kDa ([Table 1](#T1){ref-type="table"}), which is close to the calculated theoretical mass (113.8 kDa) for a 1:1 complex of the two proteins ([Table 1](#T1){ref-type="table"}). The relatively wide mass range seen for both samples reflects the observed proteolytic events leading to heterogeneity of the TorA sample observed by SDS/PAGE ([Figure 2](#F2){ref-type="fig"}). Overall, the SEC--MALLS analyses point to complexes containing one TorA protein and one TorD protein, and suggest strongly that TorD can remain stably bound to TorA in the absence of the twin-arginine signal peptide.

###### The apparent molecular masses of TorAD complexes

Parameters obtained from SEC--MALLS analysis of each of the indicated complexes.

  Sample                   Major peak elution range (min)   Molecular mass at peak (kDa)   Range across peak (kDa)   Predicted molecular mass of a 1:1 complex (kDa)
  ------------------------ -------------------------------- ------------------------------ ------------------------- -------------------------------------------------
  TorA--TorD*^His^*        26.4--30.4                       114.7                          100--120                  117.9
  TorA~ΔSP~--TorD*^His^*   26.3--30.0                       108.2                          95--115                   113.8
  TorA~ΔCT~--TorD*^His^*   27.6--30.2                       99.7                           97--107                   99.2

The TorA C-terminal domain is protease-accessible in TorAD complexes
--------------------------------------------------------------------

To gain more insight into the architecture of the TorAD complexes under investigation in the present study, limited proteolysis experiments were undertaken. First, the purified TorA--TorD*^His^* complex was incubated with a low concentration of trypsin over a time course of 60 min. As shown in [Figure 3](#F3){ref-type="fig"}(A), TorD*^His^* was almost completely resistant to trypsinolysis under these conditions. In contrast, TorA was cleaved to yield a stable proteolytic fragment of approximately 70 kDa that was apparently resistant to further digestion by trypsin. Peptide mass fingerprinting of the stable 70 kDa TorA proteolysis product revealed that the initial 675 amino acid residues from the N-terminus of the protein were intact and that the trypsin treatment had therefore removed a short section of polypeptide from the C-terminal end of TorA (Supplementary Figure S1).

![Limited trypsinolysis of the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes\
The TorA--TorD*^His^* (**A**) and TorA~ΔSP~--TorD*^His^* complexes (**B**) were isolated. Each purified complex was incubated with trypsin and 5 μl aliquots removed at 5 min intervals between 0 and 60 min, mixed with Laemmli buffer and immediately boiled to prevent any further digestion. (**C**) As a control, periplasmic mature TorA*^His^* was purified and incubated with trypsin before 5 μl aliquots were removed at the following eight time points (0 min, 10 min, 20 min, 30 min, 1 h, 2 h, 4 h and 16 h). Concomitantly, mature TorA*^His^* incubated without trypsin before aliquots were removed at the following six time points (0 min, 10 min, 30 min, 1 h, 4 h and 16 h). Samples were mixed with Laemmli buffer and immediately boiled. At the end of the time courses, the samples were analysed by SDS/PAGE (12% gels). Molecular masses are indicated in kDa.](bj2012-1832i003){#F3}

Next, the TorA~ΔSP~--TorD*^His^* complex, where TorA had already had its 39-residue signal peptide deliberately removed, was incubated with trypsin in a similar manner. As shown in [Figure 3](#F3){ref-type="fig"}(B), TorD*^His^* was almost completely resistant to protease digestion, whereas the TorA~ΔSP~ was degraded to a smaller stable product. Analysis of this protease-resistant fragment by tryptic peptide mass fingerprinting showed that it was cleaved at Lys^675^, which was the identical position where the full-length TorA precursor was cleaved. As a control, a C-terminally His-tagged, but otherwise native, form of TorA was purified from the periplasm of *E. coli* strain FTH007. The fully folded mature form of TorA was completely resistant to digestion with trypsin, even after a 16-h incubation period ([Figure 3](#F3){ref-type="fig"}C). These results are consistent with the suggestion that the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes have a similar overall architecture, both being susceptible to limited trypsinolysis in an identical manner. In both cases, a C-terminal stretch of immature TorA is obviously exposed to the aqueous phase in a conformation that is clearly not adopted by the mature fully assembled enzyme.

The C-terminal domain of TorA is not involved in stable TorAD complex formation
-------------------------------------------------------------------------------

TorA is a member DMSO reductase family of molybdoenzymes. Proteins in this family adopt a fold that can be divided into four structurally distinct domains \[[@B31]\], and, of these, Domain IV is formed by the extreme C-terminal part of the protein and is the only domain in this fold that comprises a clear contiguous stretch of polypeptide chain (Supplementary Figure S2 at <http://www.biochemj.org/bj/452/bj4520057add.htm>). Although the crystal structure of the *E. coli* TorA protein has not been solved, structure predictions based on the *Shewanella massilia* TorA crystal structure \[[@B32]\] suggest the position of the trypsin cleavage site in the *E. coli* TorA--TorD*^His^* complexes lies within an unstructured loop region that connects Domain III to Domain IV (Supplementary Figure S2). To investigate this further, a construct was designed that would co-overproduce TorD*^His^* together with the first 675 amino acids of TorA, including the signal peptide (designated TorA~ΔCT~). First, the construct was expressed in a strain lacking endogenous TMAO reductase activity under strict anaerobic conditions, which would induce expression of the MGD biosynthetic machinery. Then a crude cell extract was prepared and the TMAO reductase activity assayed. The resultant data showed that the C-terminally truncated form of TorA was completely devoid of enzymatic activity (Supplementary Table S1 at <http://www.biochemj.org/bj/452/bj4520057add.htm>), establishing that this domain of the protein is absolutely critical for function. Next, TorD*^His^* was isolated from the soluble cell fraction by IMAC, which resulted in a protein of the expected size of TorA~ΔCT~ co-purifying ([Figure 4](#F4){ref-type="fig"}). The two proteins remained fully associated during SEC through a Superdex 200 column ([Figure 4](#F4){ref-type="fig"}A), with the complex eluting with an estimated molecular mass of 100 kDa ([Figure 4](#F4){ref-type="fig"}A). Analysis of the peak fractions by SDS/PAGE confirmed that both proteins were present in the sample, but this time very little degradation of the deliberately truncated TorA was apparent ([Figure 4](#F4){ref-type="fig"}B). SEC--MALLS analysis of the purified complex ([Table 1](#T1){ref-type="table"}) confirmed that the TorA~ΔCT~--TorD*^His^* complex had a narrow mass range of 97--107 kDa, reflecting the relative homogeneity of the sample, and a peak mass of 99.7 kDa, which is close to the calculated mass (99.2 kDa) for a 1:1 complex of the two proteins ([Table 1](#T1){ref-type="table"}). It can be concluded that, although the C-terminal 173 amino acids are essential for the ultimate enzymatic activity of TorA, they do not influence the formation or stability of the pre-export complex between TorA and TorD.

![Domain IV of TorA is not required for complex formation with TorD\
(**A**) TorD*^His^*-containing fractions after metal chelate chromatography of cell extracts overproducing TorA~ΔCT~ and TorD*^His^* were pooled, concentrated and applied to a HiLoad 16/60 Superdex 200 Prep Grade size-exclusion column. Eluted protein was monitored by measuring absorbance at 280 nm. MW, molecular mass. (**B**) SDS/PAGE analysis (12% gels) of the pooled fractions after metal chelate chromatography (Ni pool), and the non-concentrated peak fraction following gel-filtration chromatography. Molecular masses are indicated in kDa.](bj2012-1832i004){#F4}

The TorAD complexes are devoid of MGD, but retain most of their secondary structure
-----------------------------------------------------------------------------------

Whereas it has generally been assumed that a Tat substrate protein is maintained in an 'unfolded conformation' when in complex with its pre-export chaperone, the degree of folding of such Tat precursors has not been examined in detail. In the present study, recombinant TorD*^His^*, active TorA*^His^*, and the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes were analysed by CD spectroscopy. The CD spectra recorded for each sample are shown in [Figure 5](#F5){ref-type="fig"} and the calculated percentages of helix, strand, turn and disorder are given in Supplementary Table S2 (at <http://www.biochemj.org/bj/452/bj4520057add.htm>). Consistent with the highly α-helical structure of TorD \[[@B17]\], the CD spectrum of purified TorD*^His^* shows a high proportion of helix ([Figure 5](#F5){ref-type="fig"} and Supplementary Table S2). Enzymes of the DMSO reductase family are mixed α/β proteins \[[@B31]--[@B34]\] and this is reflected in the CD spectrum of purified TorA*^His^* ([Figure 5](#F5){ref-type="fig"} and Supplementary Table S2). Interestingly, CD analysis of the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes showed that both had a significant degree of secondary structure and that the observed percentage of disorder was no higher than that of isolated fully assembled TorA*^His^*. Using the parameters determined for TorA*^His^* and TorD*^His^* (Supplementary Table S2), the predicted percentages of helix, strand, turn and disorder that would be expected for a simple 1:1 mixture of these two proteins can be calculated (Supplementary Table S2). It is notable that these predicted values are a close match to those experimentally determined for the purified TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes, with the values particularly close for the TorA--TorD*^His^* complex (Supplementary Table S2). Taken together, these results indicate that the TorA component of the TorA--TorD*^His^* complex has probably adopted its native secondary structure. Moreover, whereas the TorA*^His^* protein was isolated from an anaerobic culture and exhibited a straw colour in solution, the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes examined were produced from cultures grown under aerobic conditions without added molybdate. As a result, they would be expected to be largely devoid of cofactor and indeed were colourless and devoid of enzymatic activity. Metal content in the complexes by ICP-MS showed that the molar ratio of molybdenum to TorA/D complex was less than 1:1000. Taken together with the trypsinolysis experiments ([Figure 3](#F3){ref-type="fig"}), these data suggest that the cofactor-free TorD-bound species of the TorA apoenzyme adopts a fold very similar to that of its fully assembled counterpart, save for an exposed C-terminal Domain IV.

![CD spectra of purified TorA*^His^*, TorD*^His^*, and the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes\
CD spectra (185--260 nm) were collected in quartz cells of 0.02 cm pathlength at 25°C with a scan speed of 10 nm/min, bandwidth of 1 nm, response of 2 s and data pitch of 0.2 nm. The buffer used was 50 mM Tris/H~2~SO~4~ (pH 7.5), 200 mM K~2~SO~4~ and 1 mM DTT, and protein concentrations were: TorA, 0.7 mg/ml; TorD, 1 mg/ml; TorA--TorD*^His^*, 1 mg/ml; and TorA~Δsp~--TorD*^His^*, 0.5 mg/ml.](bj2012-1832i005){#F5}

SAXS analysis of full-length TorA--TorD*^His^* and signal peptide-less TorA~ΔSP~--TorD*^His^* complexes reveals shared structural features
------------------------------------------------------------------------------------------------------------------------------------------

SAXS is a powerful technique that can be used to compare the overall shapes and sizes of proteins in solution. We analysed the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes, together with isolated TorD*^His^*, since the high-resolution structure of TorD from *S. massilia* suggested that the protomer could adopt a highly extended conformation \[[@B17]\]. Representative SAXS scattering curves from each of the three samples are shown in [Figure 6](#F6){ref-type="fig"}. It is clear that the scattering curves for the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes are almost indistinguishable, indicating that they have an identical overall shape. An overview of the general parameters extracted from the SAXS data including the radii of gyration (*R*~g~; obtained from the Guinier approximation \[[@B35]\]), the distance distribution function, *P*(*r*) and the maximum particle size (*D*~max~; obtained from the GNOM \[[@B36]\] analysis) are given in [Table 2](#T2){ref-type="table"}.

![SAXS characterization of TorD*^His^* alone and TorD*^His^* in complex with different forms of TorA\
(**A**) SAXS results for TorD*^His^*, and the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes. *Q* is the scattering vector and *I* represents intensity. (**B**) Distance distributions *P*(r) for TorD*^His^*, TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^*. All curves were normalized.](bj2012-1832i006){#F6}

###### SAXS parameters for the TorA and TorD proteins

This output was obtained from the scattering data and GNOM modelling for each of the indicated protein samples.

  Sample                   *R*~g~ (Guinier)   *R*~g~ \[*P*(*r*)\]   *D*~max~ \[*P*(*r*)\]
  ------------------------ ------------------ --------------------- -----------------------
  TorA--TorD*^His^*        35.0 Å             35.2 Å                119 Å
  TorA~ΔSP~--TorD*^His^*   35.6 Å             35.1 Å                119 Å
  TorD*^His^*              20.0 Å             19.2 Å                55 Å

A low-resolution model of TorD*^His^*, obtained using the program DAMMIN \[[@B37]\], is shown in [Figure 7](#F7){ref-type="fig"}(A). The overall shape of TorD*^His^* is compact and elliptical with dimensions of approximately 36 Å×50 Å×34 Å. From the crystal structures of *S. massilia* TorD \[[@B17]\] and the TorD family protein DmsD from *E. coli* \[[@B38]--[@B40]\], scattering envelopes can be calculated \[[@B41]\]. It is clear from Supplementary Figure S3 (<http://www.biochemj.org/bj/452/bj4520057add.htm>) that neither the *S. massilia* TorD domain-swapped dimer nor one of the protomers involved in forming that dimer would give scattering curves similar to that measured for TorD*^His^* in solution. By contrast, the scattering curve predicted from the X-ray structure of DmsD is very similar in shape, and the electron density of monomeric DmsD, which can be readily docked into the TorD*^His^* SAXS envelope ([Figure 7](#F7){ref-type="fig"}B).

![*Ab initio* modelling of TorD*^His^* and the TorA--TorD*^His^* complex\
(**A**) Two different views of the *ab intio* model of TorD, generated using DAMMIN \[[@B37]\]. (**B**) The electron density for *E. coli* DmsD (PDB code 3CW0 \[[@B39]\]) docked into the SAXS-derived shape of TorD*^His^*. (**C**) and (**D**) represent two different views of the *ab intio* model of the TorA--TorD*^His^* complex. The X-ray structure of *S. massilia* TorA (PDB code 1TMO \[[@B32]\]) is shown to the right.](bj2012-1832i007){#F7}

Since the scattering curves indicated that the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes were indistinguishable, a single SAXS-derived shape corresponding to either the TorA--TorD*^His^* or the TorA~ΔSP~--TorD*^His^* complex is shown in [Figures 7](#F7){ref-type="fig"}(C) and [7](#F7){ref-type="fig"}(D). The complex is highly elongated, with an overall length of approximately 120 Å. There is a large central area of density with one relatively large lobe of density protruding from one side of the central region and a smaller lobe of density protruding from the opposite side. The large central area has approximate dimensions of 70 Å×74 Å×44 Å and is a reasonably close match to the dimensions of the crystal structure of *S. massilia* TorA ([Figures 7](#F7){ref-type="fig"}C and [7](#F7){ref-type="fig"}D).

DISCUSSION
==========

The process of co-ordinated assembly ('proofreading' or 'quality control') is an important consideration in the biosynthesis of all complex cofactor-containing Tat-dependent enzymes \[[@B5]\]. The simplest model system used to study this process is the *E. coli* TMAO reductase, which has a single MGD cofactor and a single biosynthetic chaperone, TorD. Whereas early research has seen analyses of the TorD--signal peptide interaction in isolation \[[@B12],[@B42]\], the present study has focused on the characterization of the entire pre-export TorAD complex.

Design of co-overproduction vectors established that untagged TorA formed a tight and stable complex with hexahistidine-tagged TorD. Surprisingly, however, despite the strong evidence for two separate TorD-binding sites on TorA \[[@B9],[@B11]\], we have clearly demonstrated using the accurate SEC--MALLS technique in conjunction with other experiments that TorD binds TorA with a 1:1 stoichiometry. Even more surprisingly, given the well-characterized interaction between TorD and the TorA signal peptide \[[@B11]--[@B15],[@B42]\], a truncated TorA enzyme completely lacking its entire 39-residue signal peptide retained the ability to interact in a stable manner with TorD. Whereas the present study clearly establishes that there is a high-affinity TorD-binding site within the mature portion of TorA, it also raises questions about the role and importance of the signal peptide interaction.

These findings can be interpreted in two possible ways. First, that the signal peptide-binding activity of TorD is of a much lower affinity than that of the second binding site within the mature TorA sequence, so much so that there is a strong bias towards the higher-affinity species during the purification protocol. Although this scenario is not impossible, recent studies place the apparent *K*~d~ for TorD binding to the isolated TorA signal peptide at 59--330 nM \[[@B12],[@B42]\], which is indicative of very tight binding such that it is likely that a detectable portion of TorA would not fail to have two TorD molecules bound. The second possibility is that the TorD-binding site within the mature portion of TorA is very close to the signal peptide-binding epitope such that a single TorD protein could interact with both simultaneously. This hypothesis would require there to be two different TorA-binding sites on a single TorD protein. Although the location of the TorA signal peptide-binding site on TorD has not yet been reported, there is a larger body of evidence available on the location of the signal peptide-binding site on another member of the TorD family, DmsD. The *E. coli* DmsD protein was the first twin-arginine signal peptide-binding chaperone to be described \[[@B43]\]. It is essential for the assembly of molybdenum-dependent DMSO reductase and selenate reductase enzymes in *E. coli* and binds to the signal peptides of those enzymes with apparent *K*~d~ values in the range 10--100 nM \[[@B43]--[@B45]\]. Genetic, biochemical and structural analyses predict the signal peptide-binding site to occupy only one face of DmsD (primarily involving residues of the N-terminal helices) and so suggests that a significant proportion the DmsD protein is not involved in signal peptide recognition \[[@B39],[@B45],[@B46]\]. This leaves the possibility, at least, that a second protein- or peptide-recognition site may be present on this type of chaperone. Indeed, variants of *E. coli* TorD have been described (C79R and L83P) that retain signal peptide-binding activity, but are impaired in their binding to mature TorA \[[@B10]\].

Further evidence for overlapping TorD-binding sites near the N-terminus of TorA come from analysis of the SAXS data obtained in the present study. To investigate the possible arrangement of TorA and TorD in the TorAD complex, rigid body modelling was undertaken using the SASREF program \[[@B47]\] and the structures of *S. massilia* TorA and *E. coli* DmsD as building blocks. To facilitate this analysis, TorA was split into two parts to give the proteolytically stable N-terminal part (Domains I--III) and the proteolytically sensitive Domain IV identified in the present study. A constraint was then applied that the last amino acid of N-terminal part should be within 10 Å of the first amino acid of Domain IV, in order to incorporate flexibility into the TorA component of the complex, again consistent with the protease accessibility results of the present study. The results from the rigid body modelling show a similar overall shape to that obtained during *ab initio* analysis (the fit of the model with the experimental data is shown in Supplementary Figure S4 at <http://www.biochemj.org/bj/452/bj4520057add.htm>). The rigid body model is shown docked into the *ab initio* SAXS-derived envelope of TorAD in [Figure 8](#F8){ref-type="fig"}. When docked into the *ab initio* model, the density for TorD fits very well into the larger protruding lobe, whereas the remainder of the *ab initio* envelope is of an appropriate volume to accommodate TorA. The C-terminal Domain IV of TorA distal from TorD fits into the smaller protruding lobe, which is consistent with the biochemical data of the present study that Domain IV is not required for interaction of TorD with TorA. Bearing in mind that the SAXS scattering curves for both signal peptide-containing and signal peptide-free TorAD complexes are identical, this must be taken as good evidence that the binding epitope for TorD on the mature portion of TorA must lie near the N-terminus and thus also near the second epitope within the signal peptide.

![Rigid body modelling of the TorA--TorD*^His^* complex\
Rigid body modelling was conducted using the homologous component parts of the complex, i.e. TorD homologue DmsD (PDB code 3CW0, shown in green), and TorA (PDB code 1TMO) split into two parts: Domains I--III (i.e. amino acids 5--629; shown in cyan) and Domain IV (amino acids 631--798; shown in magenta). Modelling was conducted using SASREF \[[@B47]\]. The generated model is docked into the TorA--TorD*^His^ ab intio* model for comparison.](bj2012-1832i008){#F8}

The CD and SAXS analyses suggest that there is a very high degree of folding by the TorA protein even in the absence of the MGD cofactor. However, it is clear that the TorA--TorD*^His^* and TorA~ΔSP~--TorD*^His^* complexes are not in the native conformation and that the C-terminal Domain IV of the TorA protein is exposed. This could suggest that the locking of Domain IV into position represents the final act in cofactor insertion. One possible role of TorD could be to prevent premature closing of the Domain IV 'flap' before MGD has bound, or, alternatively, that closing of Domain IV after cofactor loading is the trigger that releases TorD from the now mature enzyme. The molecular mechanism of how TorD senses the events surrounding cofactor loading remains to be unearthed.
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